Does industry-sponsored education foster overdiagnosis and overtreatment of depression, osteoporosis and over-active bladder syndrome? An Australian cohort study [PDF]
, 2018 ObjectivesTo investigate patterns of industry-sponsored educational events that focus on specific health conditions for which there are concerns about overdiagnosis and overtreatment.Design and settingThis retrospective cohort study examines publicly ...
Bero, Lisa +5 more
core +1 more source
Current indications for denosumab in benign bone tumours
EFORT Open Reviews, 2023 Denosumab is a fully humanised monoclonal antibody to RANK ligand, inhibiting the RANK–RANKL pathway. It promotes the apoptosis of osteoclast-like giant cells, a secondary ossification and connective tissue formation. Given its high efficacy, denosumab
Antal Imre +2 more
doaj +1 more source
Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
JCEM Case Reports, 2023 Denosumab is a RANK-L inhibitor used off-label as a treatment for a variety of pediatric bone disorders, including aneurysmal bone cysts (ABC). Rebound hypercalcemia is a known side effect after denosumab therapy and is more commonly reported in ...
Anne Gandolfi, Sarah Shaaban
semanticscholar +1 more source
The dental management of patients at risk of medication-related osteonecrosis of the jaw: New paradigm of primary prevention [PDF]
, 2018 Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse reaction of antiresorptive and antiangiogenic agents; it is a potentially painful and debilitating condition that can considerably affect the quality of life of patients ...
Bedogni, Alberto +7 more
core +2 more sources
Osteoporosis International, 2023 Summary In postmenopausal women with osteoporosis, up to 10 years of denosumab treatment significantly and continuously improved bone microarchitecture assessed by tissue thickness–adjusted trabecular bone score, independently of bone mineral density ...
D. Hans +5 more
semanticscholar +1 more source
Bone Reports, 2020 Discontinuation of denosumab is associated with the increase of bone turnover markers to above-baseline levels (so-called rebound in bone turnover) and rapid bone loss.
Masafumi Kashii +3 more
doaj +1 more source
Osteoporosis International, 2023 Summary This registry-based study of 3068 patients with osteoporosis compared the anti-fracture effectiveness of denosumab versus bisphosphonates. Denosumab was associated with significantly greater risk reduction than alendronate or ibandronate for ...
J. Everts‐Graber +8 more
semanticscholar +1 more source
Effect of Denosumab or Alendronic Acid on the Progression of Aortic Stenosis
Circulation, 2021 Supplemental Digital Content is available in the text. Background: Valvular calcification is central to the pathogenesis and progression of aortic stenosis, with preclinical and observational studies suggesting that bone turnover and osteoblastic ...
T. Pawade +22 more
semanticscholar +1 more source
Emerging treatments for recurrent prostate cancer [PDF]
, 2015 Despite radical treatment, many men with prostate cancer will develop recurrence of their disease. In an exciting era of new therapies for prostate cancer in general, we focus on how these will specifically benefit those men with recurrent disease.
Hanna, Catherine, Jones, Robert J.
core +1 more source
Effect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexate to Validate inhibitory effect on bone Erosion (DRIVE)-a 12-month, multicentre, randomised, double-blind, placebo-controlled, phase II clinical trial [PDF]
, 2015 OBJECTIVES: To evaluate efficacy and safety of three different regimens of denosumab, a fully human monoclonal antibody to receptor activator of nuclear factor kappa B (RANK) ligand (RANKL), for Japanese patients with rheumatoid arthritis (RA). METHODS:
Genant, Harry K. +8 more
core +1 more source